Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...

Share on Pinterest Researchers say brain lesions don’t appear to be connected to severe disability in multiple sclerosis. SeventyFour/Getty Images About 1 million people in the United States live with ...

"[These results] show that white matter lesions across all MS patients tend to injure the white matter depression network, which may create a vulnerability for depression in the MS population as a ...

The combination of cortical lesions and central vein sign in MRI increases the specificity and sensitivity for diagnosing multiple sclerosis. This study suggests that CLs and CVS, when used together, ...

Collaborating scientists at the Karolinska Institute and at Stockholm University used a technology called in situ sequencing (ISS) to help reveal at the cellular level how lesions in multiple ...

Using advanced methodology, scientists have been able to reveal at the cellular level how lesions in multiple sclerosis develop. Using advanced methodology, scientists in Sweden were able to reveal at ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

In contrast to traditional measures, such as an increase or worsening of lesions or overall brain atrophy, to signal progression of multiple sclerosis (MS), investigators are proposing atrophied ...

A phase 3 clinical trial tested the safety and efficacy of teriflunomide, an oral immunomodulatory drug, in children with multiple sclerosis. Although the medication did not prevent disease relapses ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

After 96 weeks, there was no difference in time to first clinical relapse of multiple sclerosis with teriflunomide compared with placebo. Teriflunomide was well tolerated - serious adverse events ...